About: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 June 1997

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) bài báo khoa học (vi) наукова стаття, опублікована в червні 1997 (uk) im Juni 1997 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunu de 1997 (ast) scientific article published on 01 June 1997 (en)
publication date	wds:Q73499190-2CFA53E1-83E5-4B54-B167-D31C7C933EF3
publication date	1997-06-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q73499190-EB037B5B-D221-45DB-BC08-66678192E65B
language of work or name	English
rdfs:label	Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (en) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (nl)
skos:prefLabel	Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (en) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (nl)
name	Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (en) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (nl)
title	wds:Q73499190-6DC45805-BA8F-4B4C-A16A-25509C8A2C61
title	Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (en)
page(s)	wds:Q73499190-32A323D8-B469-41F5-8004-44F9876C2544
page(s)	1857-1863
instance of	wds:Q73499190-2BAA217C-0FBC-4376-ADEF-07EC12F31E1A
instance of	scholarly article
main subject	wds:Q73499190-A0EDD89C-97C3-4702-9853-F658EF98B83F wds:Q73499190-BEE4EA0F-6EF0-47C1-8D8F-016B0BEA9AF2
main subject	placebo placebo-controlled trial
PubMed ID	wds:Q73499190-6279FEDC-8638-4D7F-8FFC-0DD93B5146C6
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9217756
PubMed ID	9217756
published in	wds:Q73499190-E52F642C-F1F3-4B96-A968-87727953D488
published in	The Lancet
issue	wds:Q73499190-BE8BDD84-1D22-47A6-A9CD-1DA8D5541315
volume	wds:Q73499190-7CC13E37-CDB7-42C8-AA6C-D379AC04DCE6
issue	9069
volume	349
number of pages	wds:Q73499190-69BF138A-915F-413A-B226-2784D0092D0C
number of pages	7 (xsd:decimal)
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73499190
is cites work of	The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. Renal protection: are all antihypertensive drugs comparable? Complement in glomerular injury Hypertension in chronic kidney disease: navigating the evidence Membranous glomerulonephritis: treatment response and outcome in children Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1 Sodium intake, ACE inhibition, and progression to ESRD. Extracorporeal shock wave therapy does not improve hypertensive nephropathy. Role of remission clinics in the longitudinal treatment of CKD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy Guidelines for the management of chronic kidney disease Dipstick proteinuria as a screening strategy to identify rapid renal decline Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy Emerging therapies for chronic kidney disease: what is their role? World Kidney Day 2011 - Protect your kidneys, save your heart Cardiovascular implications of proteinuria: an indicator of chronic kidney disease Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes Sickle cell disease in children Health-related quality of life in hypertension, chronic kidney disease, and coexistent chronic health conditions Cost-effectiveness of chronic kidney disease mass screening test in Japan The renin-angiotensin system in glomerular podocytes: mediator of glomerulosclerosis and link to hypertensive nephropathy Renal outcome in adults with renal insufficiency and irregular asymmetric kidneys Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America Roles of lymphocyte kv1.3-channels in the pathogenesis of renal diseases and novel therapeutic implications of targeting the channels. Slowing nephropathy progression: focus on proteinuria reduction Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension. Enalapril in children with Alport syndrome Blood lead level and measured glomerular filtration rate in children with chronic kidney disease Molecular targets for treatment of kidney fibrosis Proteinuria and its relation to cardiovascular disease The RAAS in the pathogenesis and treatment of diabetic nephropathy Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study Significance of the duration of nephropathy for achieving clinical remission in patients with IgA nephropathy treated by tonsillectomy and steroid pulse therapy CKiD (CKD in children) prospective cohort study: a review of current findings. Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo-Controlled Clinical Trial The HALT polycystic kidney disease trials: design and implementation Remission of renal disease: recounting the challenge, acquiring the goal ACE inhibition is renoprotective among obese patients with proteinuria Antioxidants in kidney diseases: the impact of bardoxolone methyl Cost-effectiveness of screening for microalbuminuria among African Americans Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Hypertensive renal damage: insights from animal models and clinical relevance Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall 1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension Managing kidney disease with blood-pressure control Blood pressure-independent impact of antihypertensive agents on cardiovascular and renal disease Inflammation and cachexia in chronic kidney disease Genetic polymorphisms of the RAS-cytokine pathway and chronic kidney disease Risk factors for progression of chronic kidney disease Kidney aging--inevitable or preventable? Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases Proteinuria: an ignored marker of inflammation and cardiovascular disease in chronic hemodialysis. Is proteinuria a plausible target of therapy? Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 171 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software